Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

CPC - классификация

AA6A61A61KA61K3A61K31A61K31/A61K31/1A61K31/14A61K31/145A61K31/18A61K4A61K47A61K47/A61K47/5A61K47/54A61K47/542A61K47/545A61K47/549A61K47/55A61K47/554A61K47/6A61K47/64A61PA61P2A61P25A61P25/A61P25/0A61P25/00A61P25/1A61P25/16A61P25/2A61P25/28A61P3A61P3/A61P3/0A61P3/00A61P4A61P43A61P43/A61P43/0A61P43/00A61P9A61P9/A61P9/0A61P9/00A61P9/1A61P9/14CC0C07C07CC07C3C07C30C07C309C07C309/C07C309/1C07C309/14C07C309/15C07C309/18C07C309/19C07C309/2C07C309/24C07DC07D2C07D20C07D207C07D207/C07D207/1C07D207/16C07D209C07D209/C07D209/2C07D209/20C07D21C07D217C07D217/C07D217/2C07D217/24C07D23C07D233C07D233/C07D233/6C07D233/64C07D28C07D285C07D285/C07D285/3C07D285/36C07D285/38C07D29C07D291C07D291/C07D291/0C07D291/02C07D3C07D31C07D317C07D317/C07D317/4C07D317/40C07D32C07D323C07D323/C07D323/0C07D323/02C07D33C07D333C07D333/C07D333/2C07D333/24C07HC07H1C07H15C07H15/C07H15/1C07H15/12C07H7C07H7/C07H7/0C07H7/02C07JC07J9C07J9/C07J9/0C07J9/00C07J9/005C07KC07K5C07K5/C07K5/0C07K5/06C07K5/060C07K5/0602C07K5/06026C07K5/0605C07K5/06052C07K5/0606C07K5/06069C07K5/0608C07K5/06086C07K5/08C07K5/080C07K5/0806C07K5/081C1C12C12PC12P1C12P11C12P11/C12P11/0C12P11/00C12P13C12P13/C12P13/0C12P13/00C12P13/001YY0Y02Y02PY02P2Y02P20Y02P20/Y02P20/5Y02P20/55

IPC - классификация

AA6A61A61KA61K3A61K31A61K31/A61K31/1A61K31/14A61K31/145A61K4A61K47A61K47/A61K47/5A61K47/54A61K47/6A61K47/64CC0C07C07CC07C3C07C30C07C309C07C309/C07C309/1C07C309/15C07C309/18C07C309/19C07C309/2C07C309/24C07DC07D2C07D20C07D207C07D207/C07D207/1C07D207/16C07D209C07D209/C07D209/2C07D209/20C07D21C07D217C07D217/C07D217/2C07D217/24C07D23C07D233C07D233/C07D233/6C07D233/64C07D28C07D285C07D285/C07D285/3C07D285/36C07D285/38C07D29C07D291C07D291/C07D291/0C07D291/02C07D3C07D31C07D317C07D317/C07D317/4C07D317/40C07D32C07D323C07D323/C07D323/0C07D323/02C07D33C07D333C07D333/C07D333/2C07D333/24C07HC07H1C07H15C07H15/C07H15/1C07H15/12C07H7C07H7/C07H7/0C07H7/02C07JC07J9C07J9/C07J9/0C07J9/00C07KC07K5C07K5/C07K5/0C07K5/06C07K5/062C07K5/068C07K5/08C07K5/083C1C12C12PC12P1C12P11C12P11/C12P11/0C12P11/00C12P13C12P13/C12P13/0C12P13/00

Цитирование НПИ

Akira, Kadota, et al., “Method and Reagent for Determining Bilirubun,” Patent Abstracts of Japan—Publication No. 09-178755 (Jul. 11, 1997).
Allen, C.F.H. et al., “Sultones as Reagents for Derivatizing Aliphatic Amines in Qualitative Organic Analysis,” Analytical Chemistry, vol. 37(1):156-158 (1965).
Ancsin, John B. et al, “The Heparin/Heparan Sulfate-binding Site on Apo-serum Amloid A: Implications for the Therapeutic Intervention of Amyloidosis,” The Journal of Biological Chemistry, vol. 27 4(11):7172-7181 (1999).
Aprile, Carlo et al, “Cardiac and pleuropulmonary AL amyloid Imaging with technetium-99m labeled aprotinin,” European Journal of Nuclear Medicine, vol. 22(12):1393-1401 (1995).
Axelrad, M.A. et al, “Further Characterization of Amyloid-Enhancing Factor,” Laboratory Investigation, vol. 47(2):139-146 (1982).
Baures, Paul W. et al, “Discovering Transthyretin Amloid Fibril Inhibitors by Limited Screening,” Bioorganic & Medicinal Chemistry, vol. 6:1389-1401 (1998).
Beilstein Registry No. 1712477, 2-leucylamino-ethanesulfonic acid, Feb. 27, 1989: Abderhalden, Emil et al, “Weitere Studien uber das Wesen von Ferment-wirkungen, ausgefuhrt mit Fermenten der Gruppe der Polypeptidasen,” Fermenlforschung, vol. 12:183-223 (1930).
Beilstein Registry No. 2272192, N-(2-Sulfo-ethyl)-benzamid, Jun. 29, 1989: Wood, J. Matthew et al, “Reactivity and the mechanisms of reactions of β-suitams with nucleophiles,” J. Chem. Soc., vol. 2:938-946 (2002).
Beilstein Registry No. 2434022, 4-Aethylamino-butan-sulfonsaeure-(1), Jul. 5, 1989: Helferich, von Burckhardet et al, “Alkylamine- und Arylaminoalkansulfonsauren Sowie Arylaminobutansultame,” Liebigs Ann. Chem., vol. 647:37-40 (1961).
Beilstein Registry No. 2846394, β-Naphthylaminomethylsulfonasaeure, (Jul. 11, 1989).
Beilstein Registry No. 2972476, 3-Benzylamino-propan-1-sulfonsaeure, Jul. 11, 1989: Dorn, Helmut et al, “Cyanathylierung und Sulfopropylierung von Phenyl-, Benzyl- und Cyclohexyl-hydrazin,” Z. Chem., vol. 7:151-152 (1967).
Beilstein Registry No. 3388511, 2-dibenzylamino-ethanesulfonic acid, Feb. 15, 1990.
Beilstein Registry No. 3948718, N-(Butyl-sulfonsaeure-(4))-DL-alanin, Mar. 19, 1991: Helferich, von Burckhardt et al, “Sultame von Aminosauren.” Liebigs Ann. Chem., vol. 651:33-42 (1962).
Beilstein Registry No. 3952462, 4-Azonia-6-phenyl-hexan-1-sulfonat, Mar. 19, 1991: Allen, C.F.H. et al, “Sultones as Reagents for Derivatizing Aliphatic Amines in Qualitative Organic Analysis,” Anal. Chem., vol. 37:156-158 (1965).
Beilstein Registry No. 4261672, 2-<«3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridyl>methyl&gt-;amino<ethane sulphonic acid, Jul. 20, 1992: Iskander, MN et al, “Transition-state analogues as inhibitors for GABA-aminotransferase,” Eur.J. Med. Chem., vol. 26:129-136 (1991).
Beilstein Registry No. 5568774, L-phenylalanyltaurine, Feb. 12, 1993: Ienaga, Kazuharu et al, “Simple Pepties. II. Syntheses and Properties of Taurine-Dipeplides Containing Neutral β-Amino Acid,” Chem. Pharm. Bull., vol. 36(1):70-77 (1988).
Beilstein Registry No. 5620601, H-α-Giu-Ser-Tau-OH, Feb. 12, 1993, Ienaga, Kazuhara et al, “Simple Peptides. III. Syntheses and Properties of Taurine-Oligopeptides Containing an Acidic α-Amino Acid,” Chem. Pharm. Bull., vol. 36(8):2796-2801 (1988).
Beilstein Registry No. 6023409, N,N-bis(2-sulfonylethyl)-1-octanamide disodium salt, Jul. 22, 1993: Tomson, R. et al., “Preparation and Properties of Surfactants of the Type of disodium Salts of N,N-BIS(2-Sulfoethyl)-1-Aikanamins,” Appl. Chem. USSR, vol. 57(9):1885-1891 (1984).
Beilstein Registry No. 7023352, N-(1′-aza-cyclopentin-2′yl)-2-aminoethane sulfonic acid, May 11, 1995: Campagna, Francesco et al, “Cyclic Amidine Analogues of Taurine and Homotaurine: Synthesis and Effects on Rat Skeletal Muscle,” II Farmaco, vol. 49(10):653-656 (1994).
Beilstein Registry No. 8919306, Microxine, Jan. 24, 2002: Killday, K. Brian et al, “Microxine, a New cdc2 Kinase Inhibitor from the Australian Marine Sponge Microxina Species,” J. Nat. Prod., vol. 64:525-526 (2001).
Berge, Stephen M. et al, “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, vol. 66(1):1-19 (1977).
Bloemen, P.G.M. et al, “Adhesion molecules: a new target for immunoliposome-mediate drug delivery,” FEBS, vol. 357:140-144 (1995).
Boismare, F. et al, “A Homotaurine Derivative Reduces the Voluntary Intake of Ethanol by Rats: are Cerebral GABA Receptors Involved?” Pharmacology Biochemistry & Behavior, vol. 21:787-789 (1984).
Briggs, Andrew D. et al, “Acyloxymethyl and 4-Acyloxybenzyl Diester Prodrugs of Phosphonoformate,” Tetrahedron, vol. 52(47):14937-14950 (1996).
Briscoe, Page et al, “Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes,” Am. J. Physiol., vol. 268:L374-L380 (1995).
Brissette, Louise et al, “Differential Induction of the Serum Amyloid A Gene Family in Response to an Inflammatory Agent and to Amyloid-enhancing Factor,” The Journal of Biological Chemistry, vol. 264(32):19327-19332 (1989).
Brittain, H.G. Polymorphism in Pharmaceutical Solids: 202-208 and 219. (1999).
Buee, L et al, “Alzheimer's disease: binding of vascular and neuroblastomer heparan sulfate proteoglycans to amyloid β protein A4,” Advances in Biosciences, vol. 87:217-218 (1993).
Cai, Xiao-Dan et al, “Release of Excess Amyloid β Protein from a Mutant Amyloid β Protein Precursor,” Science, vol. 259:514-516 (1993).
Campagna. Francesco et al, “Cyclic Amidine Analogues of Taurine and Homotaurine: Synthesis and Effects of Rat Skeletal Muscle,” II Farmaco, vol. 49(10):653-658 (1994).
Carretero, J.C. et al., “Synthesis of α,β-epoxysulphonic acids as potential inhibitors of bacterial D,D-peptidases,” Bulletin de la Societe Chimique de France, vol. 6:835-842 (1990).
Caughey, B., “Protease-resistant PrP accumulation and scrapie agent replication: a role for sulphated glycosaminoglycans?” Biochemical Society Transactions, 648th Meeting Belfast, vol. 22:163-167 (1994).
Caughey, B., “Scrapie associated PrP accumulation and its prevention: insights from cell culture,” British Medical Bulletin, vol. 49(4):860-872 (1993).
Caughey, Byron et al, “Binding of the Protease-Sensitive Form of Prion Protein PrP to Sulfated Glycosaminoglycan and Congo Red,” Virology, vol. 68(4):2135-2141 (1994).
Caughey, Byron et al, “Sulfated Polyanion Inhibition of Scrapie-Associated PrP Accumulation in Cultured Cells,” Journal of Virology, vol. 67(2):643-650 (1993).
Caughey, Byron, “Scrapie-associated PrP accumulation and agent replication: effects on sulphated glycosaminoglycan analogues,” Phil. Trans. R. Soc. Lond. B., vol. 343:399-404 (1994).
Cerovsky et al, “Enzymatic approach to the synthesis of taurine-containing peplides”, Int. J. Peptide & Protein Res., 44(5), 466-471 (1994).
Chabenat, C. et al, “Physicochemical, Pharmacological and Pharmacokinetic Study of a New GABAergic Compound, Calcium Acetylhomotaurinate,” Meth and Find Exptl Clin Pharmacol., vol. 10(5):311-317 (1988).
Chan and Bruce, “Characterization and One-Two-Electron Redox Chemistry of 1,5-Dicarba-1,5-dideazaisoalloxazines (Flavins),” J. Am. Chem. Soc. 100(23):7375-7382 (1978).
Chauvel, Eric N. et al., “Differential Inhibition of Aminopeptidase A and Aminopeptidase N by New β-Amino Thiols,” J. Med. Chem., vol. 37:2950-2957 (1994).
Chishti, M. Azhar et al, “Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695,” The Journal of Biological Chemistry, vol. 276(24):21562-21570 (2001).
Colon, Wilfredo et al, “Partial Denautration of Transthyretin is Sufficient for Amyloid Fibril Formation in Vitro,” Biochemistry, vol. 31:8654-8660 (1992).
Copani, A. et al, “Activation of Metabotropic Glutamate Receptors Protects Cultured Neurons Against Apoptosis Induced by β-Amyloid Peptide,” Molecular Pharmacology, vol. 47:890-897 (1995).
David, Christelle et al., “Investigation of Subsite Preferences in Aminopeptidase A (EC 3.4.11.7) Led to the Design of the First Highly Potent and Selective Inhibitors ofThis Enzyme,” J. Med. Chern., vol. 42:5197-5211 (1999).
De Strooper, Bart et al, “Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein,” Nature, vol. 394:387-390 (1998).
DeMattos, Ronald B. et al, “Brain to Plasma Amloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease,” Science, vol. 295:2264-2267 (2002).
Doctor's Guide Global Edition, “Alzhemed Showing Continued Positive Interim Results After 20 Months in Patients With Alzheimer's Disease”, http://psigroup.com/dq/244952.htm. (Jul. 19, 2004).
Dow, Kimberly E. et al, “Effects of 4-deoxy-L-threo-pentose, a novel carbohydrate, on neural cell proteoglycan synthesis and function,” Biochemica et Biophysica Acta, vol. 1156:7-14 (1992).
Durbin, PH et al, “Evidence of Acamprosate Penetration into the Rat Brain,” Behavioural Pharmacology, vol. 6:620 (1995).
Ehlers, Bernhard et al, “Dextran Sulphate 500 Delays and Prevents Mouse Scrapie by Impairment of Agent Replication in Spleen,” The Journal of General Virology, vol. 65:1325-1330 (1984).
Eisai America, Inc., “Aricept.” Center Walch, Inc. http://www.centerwalch.com/patient/drugs/dru190.110-41. (Copyright 1995-1996).
Enders, D. et al., “A Highly Efficient Asymmetric Syntiesis of Homotaurine Derivatives via Diastereoselective Ring—Opening of γ-Sultones,” Synthesis, vol. 17:2910-2918 (2004).
Entry for solvate, Free Dictionary, http://www.thefreedictionary.com/solvate, accessed online on Jul. 21, 2009.
Espacenet Bibliographic data: JP2002503700 (A)—Feb. 5, 2002 “Novel Disulfides and Thiol Compounds”.
Espacenet Bibliographic data: JP2002509104(A)—Mar. 26, 2002, “Methods of Treating Tardive Dyskinesia and Other Movement Disorders”.
Espacenet Bibliographic data: WO 0206214 (A1) Jan. 24, 2002—“Sulfonic Acid Derivatives of Hydroxamic Acids and Their Use as Medicinal Products”.
European Search Report, EP appl. No. 14200552.9, 14 pages (dated Jul. 10, 2015).
Fraser, Paul E. et al, “Effects of Sulfate Ions on Alzheimer β/A4 Peptide Assemblies: Implications for Amyloid Fibril-Proteoglycan Interactions,” Journal of Neurochemistry, vol. 59:1531-1540 (1992).
Fraser, Paul E. et al, “Fibril Formation by Primate, Rodent, and Dutch-Hemorrhagic Analogues of Alzheimer Amyloid β-Protein,” Biochemistry, vol. 31:10716-10723 (1992).
Fujii, Akira et al, “Probiotics. Antistaphylococcal and Antifibrinolytic Activities of ω-Amino- and ω- Guanidinoalkanesulfonic Acids,” Journal of Medicinal Chemistry, vol. 18(5):502-505 (1975).
Galli et al., “Interaction of N-Acyl and N-Sulfonyl Derivatives of Sulfonic Amino Acids with3H-Gaba Binding Sites in Rat Brain,” in Advances in Pharmacological Research and Practice, Proceedings of the 3rd Congress of the Hungarian Pharmacological Society, Budapest, 1979, Vollume II. Modulation mof Neurochemical Transmission, pp. 403-415 (1979).
Gervais et al., “Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis,” Neurobiol Aging.;28(4):537-47 (Apr. 2007).
Gervais, Francine et al., Proteoglycans and Amyloidogenic Proteins in Preipheral Amyloidosis,“Curr Med. Chem—Immun. Endoc. & Metab. Agents,” 3:361-370 (2003).
Gervais, Francine, “Amyloid—Those Deadly Fibrils,” Eur. Biopharm. Review, pp. 40-42 (2001).
Girault. J. et al. “Determination of calcium acetylhomotaurinate in human plasma and urine by combined gas chromatography-negative-ion chemical ionization mass spectrometry,” Journal of Chromatography, vol. 530(2):295-305 (1990).
Gorin, Boris I. et al, “A Novel Esterification Procedure Applied to Synthesis of Biologically Active Esters of Foscarnet,” Tetrahedron Letters, vol. 38(16):2791-2794 (1997).
Gottlieb, “Brain changes may link Alzheimer's and Parkinson' diseases,” Br. Med. J.; 323(7316): 771 (Oct. 6, 2001).
Grant, KA et al, “Reinforcing and Discriminative Stimulus Effects of Ca-Acetyl Homotaurine in Animals,” Pharmacology, Biochemistry & Behavior, vol. 32:607-611 (1989).
Greenberg et al., “A phase 2 study of tramiprosate for cerebral amyloid angiopathy,” Alzheimer Dis Assoc Disord.;20(4):269-74 (Oct.-Dec. 2006).
Hamazaki, Hideaki et al, “Calcium-dependent polymerization of human serum amyloid P component is inhibited by heparin and dextran sulfate,” Biochemica et Biophysica Acta, vol. 998:231-235 (1989).
Hamazaki, Hideaki, “Ca2+-medialed Assocation of Human Serum Amyloid P Component with Heparan Sulfate and Dennatan Sulfate,” The Journal of Biological Chemistry, vol. 262(4):1456-1460 (1987).
Hamilton, Ronald L, “Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α-Synuclein Immunohistochemistry,” Brain Pathology, vol. 10:378-384 (2000).
Han, Hogyu et al, “The core Alzheimer's peptide NAC fonns amyloid fibrils which seed and are seeded by β-amyloid: is NAC a common trigger or target in neurodegenerative disease?” Chemistry & Biology, vol. 2:163-169 (1995).
Harriman et al., “Radiation Chemistry of Cyanine Dyes: Oxidation and Reduction of Merocyanine 540,” J. Phys. Chem. 95:2415-2420 (1991).
Hawkins, P.N., “Diagnosis and monitoring of amyloidosis,” Bailliere's Clinical Rheumatology, vol. 8(3):635-659 (1994).
Helferich, Burckhardt et al., “Uber Sultame, VIID, Sultame von Aminosauren,” Liebigs Annalen der Chemie, vol. 651:33-42 (1962).
Hirai, Hisao, et al., Synthesis and Some Surface Active Properties of Fatty Derivatives of Propane Sultone, 469-474 (Sep. 15, 1966).
Hirofumi, Sano, et al., Production of Hot Water-Resistant Polyvinyl Alcohol-Based Fiber, Patent Abstracts of Japan—Publication No. 04-153311 (Jun. 8, 1992).
Hutchings, R. et al, “The Effect of Excitotoxin Antagonists on Ibolenic Acid-Induced Alteration of APP MRNA Hippocampal Expression,” J. Pharmacy and Pharmacology, vol. 47(12B):1131 (1995).
International Search Report for Application No. PCT/IB2004/002375, dated Jul. 13, 2005.
International Search Report for Application No. PCT/IB2005/004166, dated Mar. 13, 2007.
Ismail, Ibrahim Imam, “Reactions with sultones II,” Afnidad vol. 446:256-258 (1993).
Ismail, Ibrahim Imam, “Reactions with sultones and sultams,” J. Serb. Chem. Soc., vol. 57(7):415-520 (1992).
Iwai, Akihiko et al, “Non-A.β Component of Alzheimer's Disease Amyloid (NAC) is Amyloidogenic,” Biochemistry, vol. 34:140139-10145 (1995).
Iwai, Akihiko, “Properties of NACP/α-synuclein and its role in Alzheimer's disease,” Biochimica et Biophysica Acta, vol. 1502:95-109 (2000).
James, Guy L et al, “Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells,” Science, vol. 260:1937-1942 (1993).
Kagan, D.Z. et al, “Congo Red Inhibition of Amylogenesis in Experimental Amyloidosis,” Problemy Tuberkuleza, vol. 40:72-74 (1974).
Kalaitzakis et al., “Striatal beta-amyloid deposition in Parkinson disease with dementia,” J Neuropathol Exp Neurol.;67(2):155-61 (Feb. 2008).
Kazuhiro, Maeda, et al., Method for Producing Sulfonic Acid Derivatives of Hydroxamic Acid, Patent Abstracts of Japan—Publication No. 2005-200314 (Jul. 28, 2005).
Kazuyuki, Tsubone, “Surfactant,” Patent Abstracts of Japan—Publication No. 10-204476 (Aug. 4, 1998).
Keinanen, Kari et al, “Biosynthetic lipid-tagging of antibodies,” FEBS, vol. 346:123-126 (1994).
Killion, Jerald J. et al, “Systemic Targeting of Liposome-Encapsulated Immunomodulators to Macrophages for Treatment of Cancer Metastasis,” Immunomethods, vol. 4:273-279 (1994).
Kisilevsky, R. et al, “The Potential Significance of Sulphate Glycosaminoglycans as a Common Constituent of all Amyloids: or, Perhaps Amyloid is not a Misnomer,” Medical Hypotheses, vol. 26:231-236 (1988).
Kisilevsky, R., “From arthritis to Alzheimer's disease: current concepts on the pathogenesis of amyloidosis,” Can. J. Physiol. Pharmacol., vol. 65:1805-1815 (1987).
Kisilevsky, Robert et al. “Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease,” Nature Medicine, vol. 1(2):143-148 (1995).
Kisilevsky, Robert, “A Critical Analysis of Postulated Pathogenetic Mechanisms in Amyloidogenesis,” Critical Reviews in Clinical Laboratory Sciences, vol. 29(1):59-82 (1992).
Kisilevsky, Robert, “Theme and Variations on a String of Amyoid,” Neurobiology of Aging, vol. 10:499-500 (1969).
Kondo et al., “Synthesis of Sulfonic Acid Derivatives of Purine and Pyrimidine,” Synthetic Commun. 10(4):261-271 (1980).
Krogsgaard-Larsen, P. et al, “Novel (Gamma-Aminobutyric Acid)A Agonists and Partial Agonists,” FIOIA Research Foundation Symposium Series (1991).
Lacoste, Anne-Marie et al, “Inhibition of D-Alanyl-D-Alanine Ligase in Different Bacterial Species by Amino Phosphonic Acids,” Current Microbiology, vol. 2:113-117 (1979).
Lee, Albert W. M. et al., “Synthesis and Diels-Alder reactions of α,β-unsaturated γ-sultone,” Chemical Communications, vol. 6:611-612 (1997).
Leveugle, B. et al, “Binding of heparan sulfate glycosaminoglycan to β-amyloid petide: inhibition by potentially therapeutic polysulfated compounds,” NeuroReport, vol. 5:1389-1392 (1994).
Lhuintre, Jean-Pierre et al, “Ability of Calcium Bis Acetyl Homotaurine, a Gaba Agonist, to Prevent Relapse in Weaned Alcoholics,” The Lancet, vol. 1(8436):1014-1016 (1985).
Li, Chun-Sing et al., “Synthesis of(±)-3-Amino 2-(4-chlorophenyl)propanesulfonic acid (Saclofen),” Synthesis, vol. 3:244 (1991).
Littleton, John, “Acamprosate in alcohol dependence: how does it work?” Addiction, vol. 90:1179-1188 (1995).
Lyon, A.W. et al, “Co-deposition of Basement Membrane Components during the Induction of Murine Splenic AA Amyloid,” Labratory Investigation, vol. 64(6):785-790 (1991).
Madamba, Samuel G. et al, “Acamprosate (Calcium Acetylhomotaurinate) Enhances the N-Methyl-D-Aspartate Component of Excitatory Neurotransmission in Rat Hippocampal CA1 Neurons In Vitro,” Alcoholism: Clinical and Experimental Research, vol. 20(4):651-658 (1996).
Malmusi, Luca et al, “1,2,3,4-Tetrahydroisoquinoline and Related Analogs of the Phenylalkylamine Designer Drug MDMA,” Med. Chem. Res., vol. 6(6):412-426 (1996).
Marnela et al., “Mass Spectrometric Analyses of Brain Synaptic Peptides Containing Taurine,” J. Neurochem. 43(6): 1650-1653 (1984).
Masliah, Eliezer et al, “Altered Presynaptic Protein NACP is Associated with Plaque Formation and Neurodegenration in Alzheimer's Disease,” American Journal of Pathology, vol. 146(1):201-210 (1996).
Masuda, Midori et al, “Effect of taurine on nonspecific protection against bacterial infection,” Database STN International, Chemical Abstracts Service, Accession No. 105:108004 (1985) (Abstract only).
Masuoka, Niroyoshi, et al., “Preparation of a Volative Derivative of Taurine and Application to Gas Chromatographic Determination of Urinary Taurine,” Ada Med Okayama 43(5) 253-259 (1989).
May, Patrick C., “Current progress on new therapies for Alzheimer's disease,” Drug Discovery Today, vol. 6(9):459-462 (2001).
McCubbin, William D. et al, “Circular-dichroism studies on two murine serum amyloid A proteins,” Biochem. J., vol. 256:775-783 (1988).
Merck Index, p. 883, Merck & Co. Inc., Rahway, N.J., USA (1989).
Mimura, Tetsutaro et al, “A Novel Class of Enkephalinase Inhibitors Containing a C-Terminal Sulfo Group,”J. Med. Chern., vol. 35:602-608 (1992).
Morgan, Barry A. et al, “Approaches to the Discovery of Non-Peptide Ligands for Peptide Receptors and Peptidases,” Ann. Rep. Med. Chern., Virick F.J. (Ed.) pp. 243-253, Academic Press, San Diego, CA (1989).
Morihiro, Wada, et al., “M Protein Detecting Method for Serum Protein Fraction,” Patent Abstract of Japan Publication No. JP5312812 (Nov. 26, 1983).
Mukaetova-Ladinska, E.B. et al, “α-Synuclein Inclusions in Alzheimer and Lewy Body Diseases,” Journal of Neuropathology and Experimental Neurology, vol. 59(5):408-417 (2000).
Nakada, Tsutomu et al, “Guanidinoethane sulfate: brain pH alkaline shifter,” NeuroReport, vol. 4:1035-1038 (1993).
Narindrasorasak, Suree et al, “Characterization of High Affinity Binding between Laminin and Alzheimer's Disease Amyloid Precursor Proteins,” Laboratory Investigation, vol. 67(5):643-652 (1992).
Narindrasorask, Suree et al, “High Affinity Interactions between the Alzheimer's β-Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan,” The Journal of Biological Chemistry, vol. 266 (20):12878-12883 (1991).
National Institute on Alcohol Abuse and Alcoholism No. 33 PH 366; “Alcohol Alerg,” http://pubs.niaaa.nih. gov/publications/aa33.htm. (Jul. 1996).
Noren, Jan O. et al, “Synthesis of Esters of Phosphonoformic Acid and Their Antiherpes Activity,” Journal of Medicinal Chemistry, vol. 26(2):264-270 (1982).
O'Brien, Timothy D. et al., “Human Islet Amyloid Polypeptide Expression in COS-1 Cells,” American Journal of Pathology, 147(3):606-616 (1995).
Owais, Mohammad et al., “Chloroquine Encapsulated in Malaria-Infected Erythrocyte-Specific Antibody-Bearing Liposomes effectively Controls Chloroquine-Resistent Plasmodium Berghei Infections in Mice,” Antimicrobial Agents and Chemotherapy, 39(1):180-184 (1995).
Panula-Lehto, Elina et al., “Comparison of the Effects of Intraventricular Taurine, GABA and Homotaurine on Serum Prolactin Levels in Male Rats,” Pharmacology and Toxicology, 65:152-156 (1989).
Partial European Search Report, EP appl. No. 14200552.9, 9 pages (Apr. 15, 2015).
Pollack, Scott J. et al., “Sulfonated Dyes Attenuate the Toxic Effects of Beta-amyloid in a structure-specific Fashion,” Neuroscience Letters, 197:211-214 (1995).
Powell, D.S. et al, “Insulin and Polyionic Sulphonates Modify Human Islet Amyloid Polypeptide Fibril Aggregation In Vitro,” Diabetologia, vol. 41 (Suppl. 1):656 (1998).
Puchtler, H. et al, “Application of Thiazole Dyes to Amyloid under Conditions of Direct Cotton Dyeing: Correlation of Histochemical and Chemcial Data,” Histochemistry, vol. 77:431-445 (1983).
Ranade, Vasant V., “Drug Delivery Systems. 1. Site-Specific Drug Delivery Using Liposomes as Carriers,” J. Clin. Pharmacol., vol. 29:685-694 (1989).
Rodier, Par P. Toffoli et N. et al, “Bis(acetamido-3 propanesulfonate-1) de Calcium (N-Acetylhomotaurinate de Calcium),” Acta Crysl., vol. C44:1493-1494 (1989).
Sadler, Isobell. J. et al, “Sulphate compounds attenuate β-amyloid toxicity by inhibiting its association with cells,” NeuroReport, vol. 7:49-53 (1995).
Sass, Henning et al, “Relapse Prevention by Acamprosate,” Arch. Gen. Psychiatry, vol. 53:673-680 (1996).
Sawada et al., “Recognition of L-Amino Acid Ester Compounds by Rat Peptide Trqansporters PEPT1 and PEPT2,” J. Pharm. Exp. Ther. 291:705-709 (1999).
Schreier, Hans et al. “Targeting of Liposomes to Cells Expressing CD4 Using Glycosylphosphatidylinositol-anchored gp120.” The Journal of Biological Chemistry. vol. 269(12):9090-9098 (1994).
Shue, Ho-Jane et al, “A Study of 3-Amino-N-Hydroxypropanesulfonamide Derivatives as Potential GABAB Agonists and Their Fragmentation to 3-Aminopropanesulfnic Acid,” Bioorganic & Medicinal Chemistry Letters, vol. 6(14):1709-1714 (1996).
Silverman, Richard B., “Prodrugs and Drug Delivery Systems,” The Organic Chemistry of Drug Design and Drug Action. Academic Press, Inc. Chapter 8, pp. 352-401, (2004).
Small, D.H. et al, “Association and Release of the Amyloid Protein Precursor of Alzheimer's Disease from Chick Brain Extracellular Matrix,” The Journal of Neuroscience, vol. 12(11);4143-4150 (1992).
Snow, A. D. et al, “Sulfated glycosaminoglycans in amyloid plaques of prion diseases,” Acta Neuropathol., vol. 77:337-342 (1989).
Snow, Alan D. et al, “A Temporal and Ultrastructural Relationship Between Heparan Sulfate Proteoglycans and AA Amyloid in Experimental Amyloidosis,” The Journal of Histochemistry and Cytochemistry, vol. 39(10):1321-1330 (1991).
Snow, Alan D. et al, “Sulfated Glycosaminoglycans in Alzheimer's Disease,” Human Pathology, vol. 18(5):506-510 (1987).
Snow, Alan D. et al, “Sulfated Glycosaminoglycans: A Common Constituent of All Amyloids?” Laboratory Investigation, vol. 56(1):120-123 (1987).
Snow, Alan D. et al, “Temporal Relationship between Glycosaminoglycan Accumulation and Amyloid Deposition during Experimental Amyloidosis,” Laboratory Investigation, vol. 53(1):37-44 (1985).
Snow, Alan David et al, “A Close Ultrastructural Relationship betweel Sulfated Proteoglycans and AA Amyloid Fibrils,” Laboratory Investigation, vol. 57(6):687-698 (1987).
Snow, Alan David et al, “Characterization of Tissue and Plasma Glycosaminoglycans during Experimental AA Amyloidosis and Acute Inflammation, Qualitative and Quantitative Analysis,” Laboratory Investigation, vol. 56(6):665-675 (1987).
St. Georgiev, Vassil et al, “Drug-Induced Modifications of the Immune Response. 1. Substituted 1-Phenylisoquinolines,” Journal of Medicinal Chemistry, vol. 22(4):348-352 (1979).
Strejan. G. H. et al, “Suppression of Chronic-Relapsing Experimental Allergic Encephalomyelitis in Strain-13 Guinea Pigs by Administration of Liposome-Associaled Myelin Basic Protein,” Journal of Neuroimmunology, vol. 7:27-41 (1984).
Takahashi, Masakatsu, New Gluocoaminosulfonic Acid Compaound and Produciton and Sulfactant Composition Containing the Same, Patent Abstracts of Japan—Publication No. 06-184089 (Jul. 5, 1994).
Takatoshi, Hattori, “Separator Column for Ion Chromatography,” Patent Abstracts of Japan—Publication No. 06-138110 (May 20, 1994).
Tape, C. et al, “Direct Evidence for Circulating apoSAA as the Precursor of Tissue AA Amyloid Deposits,” Scand. J. Immunol. vol. 26:317-324 (1988).
Thompson et al., Curent Medicinal Chemistry, 9(19), pp. 1751-1762. (Oct. 2002).
Toshimasa, Tokuda, Flame-Retardant Ploycarbonate Resin Composition—Patent Abstracts of Japan, Publication No. 54-106560 (Aug. 21, 1979).
Travis, John, “New Piece of Alzheimer's Puzzle,” Science, vol. 261:828-829 (1993).
Truce, William E. et al., “The Chemistry of Sultones. I. Friedel-Crafts Reaction to Sultones,” Journal of the American Chemical Society, vol. 76(21):5357-5360 (1954).
Tugcu et al., “Synthesis and Characterization of High-Affinity, Low-Molecular-Mass Displacers for Anion-Exchange Chromatography,” Ind. Eng. Chem. Res. 41:6482-6492 (2002).
Ueda, Kenji et al, “Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease,” Proc. Natl. Acad. Sci. USA, vol. 90:11282-11286 (1993).
Uemzawa, F. et al, “Liposome Targeting to Mouse Brain: Mannose as a Recognition Marker,” Biochemical and Biophysical Research Communications, vol. 153(3):1038-1044 (1988).
Varga, V. et al., “Modulation of GABAergic Neurotransmission in the Brain by Dipeptides,” Nuerochem. Res., 13 (11):1027-1034 (1998).
Vippagunta et al., “Crystalline solids,” Advanced Drug Delivery Reviews, 48, p. 3-26. (2001).
Visser and Fendler, “Deazaflavin Photocatalyzed Methyl Viologen Reduction in Water. A Laser Flash—Photolysis Study,” J. Phys. Chem. 66:2406-2409 (1982).
Westermark, P., Islet Pathology of Non-Insulin-dependent Diabetes Mellitus (NIDDM), Diabetic Medicine, vol. 13:S46-S48 (1996).
Whitworth, A. et al, “Is Acamprosate an Effective Treatment for Alcohol Dependence?” The Lancet, vol. 347:1438-1442 (1996).
Willems. J. et al.. “The aliphatic hydroxysulphonic acids and their internal esters: the sultones. Part II. The Sultones.” Bulletin des Societes Chimiques Belges, vol. 64:747-771 (1955).
Wong, S. et al, “Influence of Sulphate Ions on the Structure of AA Amyloid Fibrils,” Scand. J. Immunol., vol. 32:225-232 (1990).
Wood, Stephen J. et al, “Selective Inhibition of Aβ Firbil Formation,” The Journal of Biological Chemistry, vol. 271 (8):4086-4092 (1996).
Yoshimoto, Makoto et al, “NACP, the precursor protein of the non-amyloid β/A4 protein (Aβ) component of Alzheimer's disease amyloid, binds Aβ and stimulates Aβ aggregation,” Proc. Natl. Acad. Sci. USA, vol. 92:9141-9145 (1995).
Young et al, “Localization of the Basement Membrane Heparan Sulfate Proteoglycan in Islet Amyloid Deposits in Type II Diabetes Mellitus,” Arch Pathol Lab Med., vol. 116:951-954 (1992).
Young et al, “The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinoma-associated amyloidosis,” Acta Neuropathol., vol. 78:202-209 (1989).
Yu et al., “Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo,” Bioorg. Med. Chem. Lett. 16:1115-1122 (2006).
Zeid et al., “Synthesis of N-substituted aminosulphonic acids,” Chemistry and Industry, 21:380 (1973).
“Definition of amino acid residue”, IUPAC Gold Book, IUPAC Compendium of Chemical Terminology, 2nd edition. (1997).
“Definition of prevent”, Oxford English Dictionary Online, http://dictionary.oed.com/, accessed online Mar. 27, 2010, especially definition 9a. at p. 2. (2010).
“Entry for Dry Macular Degeneration”, Mayo Clinic website, https://www.mayoclinic.org/, accessed online on Feb. 13, 2020. (2020).